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Introduction: In non-small cell lung cancer (NSCLC), the presence
of locoregional lymph node metastases remains the most important
prognostic factor and significantly guides treatment regimens. Un-
fortunately, currently-available noninvasive staging modalities have
limited accuracy. The objective of this study was to create a
multianalyte blood test capable of discriminating a patient’s true
(pathologic) nodal status preoperatively.
Methods: Pretreatment serum specimens collected from 107 NSCLC
patients with localized disease were screened with 47 biomarkers
implicated in disease presence or progression. Multivariate statistical
algorithms were then used to identify the optimal combination of
biomarkers for accurately discerning each patient’s nodal status.
Results:We identified 15 candidate biomarkers that met our criteria for
statistical relevance in discerning a patient’s preoperative nodal status.
A ‘random forest’ classification algorithm was used with these param-
eters to define a 6-analyte panel, consisting of macrophage inflamma-
tory protein-1, carcinoembryonic antigen, stem cell factor, tumor
necrosis factor-receptor I, interferon-, and tumor necrosis factor-,
that was the optimum combination of biomarkers for identifying a
patient’s pathologic nodal status. A Classification and Regression Tree
analysis was then created with this panel that was capable of correctly
classifying 88% of the patients tested, relative to the pathologic assess-
ments. This value is in contrast to our observed 85% classification rate
using conventional clinical methods.
Conclusions: This study establishes a serum biomarker panel with
efficacy in discerning preoperative nodal status. With further validation,
this blood test may be useful for assessing nodal status (including occult
disease) in NSCLC patients facing tumor resection therapy.
Key Words: Biomarker, Serum, Non-small cell lung cancer, Nodal
status, Luminex.
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Lung cancer is the most common cause of cancer relatedmortality worldwide. In the USA, over 200,000 new cases
will be diagnosed this year with the majority having advanced
disease not amenable to potentially curative surgery.1 Non-
small cell lung cancer (NSCLC) accounts for 80 to 85% of all
lung cancer cases and is comprised of three major histopatho-
logical subtypes, which include adenocarcinoma, squamous
cell carcinoma, and large cell carcinoma.
Approximately 25% of NSCLC patients present with
localized, early-stage disease. Surgical resection with accompa-
nying lymph node sampling/dissection remains the cornerstone
of current treatment for these patients and clearly improves
patient outcome.2 Accurate lymph node staging is crucial to the
optimal clinical management of NSCLC and remains the fore-
most prognostic factor for patient outcome with localized tu-
mors.3 Unfortunately, micrometastatic disease is often missed by
conventional pathologic analysis (hematoxylin and eosin stain-
ing). With this, the risk of disease recurrence and death remains
substantial even in early-stage patients; with 5-year survival
rates for pathologic stage I and II disease of 57 to 85% and 38
to 65%, respectively.1 The use of adjuvant (postoperative) che-
motherapy to obviate disease recurrence for all patients receiv-
ing tumor resection is an attractive idea, but remains a contro-
versial subject. That is, although the population of resected
patients with stage I-IIIa NSCLC receive a considerable survival
advantage from adjuvant chemotherapy,4 unselected subpopula-
tions of stage I patients do not receive a statistical benefit.5
Methods that could identify stage I patients with occult
micrometastatic disease would provide a means to select
for which patients may gain a survival benefit from sys-
temic therapy as part of their postoperative care. New
diagnostic tests based on molecular information from the
primary tumor are urgently needed to enhance current
staging protocols and identify which patients have occult
micrometastatic disease.
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A variety of approaches has been documented in the
literature designed to better stage patients using molecular
methods. Perhaps most notable of these were the studies that
investigated associations between the patterns of gene expres-
sion and specific clinical parameters, such as lymph node
metastasis6–9 or prognosis.10,11 Relevant to the objectives of
this study, Choi et al. were able to identify several multigene
expression signatures from microarray data sets that each
have value in predicting lymph node metastases in NSCLC
patients.6–9,12,13 These multigene panels survey a range of
known tumor-associated biologic pathways (including cell
cycle regulation, apoptosis, and angiogenesis) and define a
‘molecular phenotype’ for the tumor.
There is mounting evidence that multianalyte panels of
biomarkers offer clear statistical advantages over individual
biomarkers for discerning diagnostic and prognostic features
across a variety of disease states, including cancer.14–17 Not
unexpectedly, the early attempts at formulating a multiana-
lyte blood test for NSCLC relied heavily on the well-charac-
terized, prognostic serum biomarkers, such as carcinoembry-
onic antigen (CEA) and the cytokeratin 19 fragment, CYFRA
21.1.18–21 Expansion of this CEA/CYFRA 21.1 combination
to include auxiliary biomarkers, such as CA125, Neuron
specific enolase, Macrophage-colony stimulating factor (M-
CSF), and tissue polypeptide antigen22–24 was also investi-
gated as a means to further improve the prognostic power of
biomarker combinations for this purpose. Soon, the benefits
of adding biomarkers such as retinol binding protein, 1-
antitrypsin, and squamous cell carcinoma antigen to the
CEA/CYFRA 21.1 combination became the focus of several
test development efforts, with the best of these boasting
72.8% sensitivity and 75.4% specificity25,26 for correctly
diagnosing patients with NSCLC. Despite the extensive de-
velopment efforts put forth by the scientific community, none
of these biomarker combinations ever passed the appropriate
validation steps to have a clinical impact. However, a series
of recent publications detailing the large-scale evaluation of
biomarkers with the Luminex immunoassay platform with
new multivariate regression methods have reinvigorated in-
terest in this multivariate approach within the cancer com-
munity.14,16,27
In this article, we use this multivariate biomarker panel
strategy to screen 107 NSCLC patients for 47 serum markers,
selected based on either documented relevance to NSCLC
progression8,19,23–25,28–35 or involvement in biologic pathways
believed to be important to metastatic progression. Our ob-
jective was to develop a multianalyte blood test to discern a
patient’s pathologic lymph node status preoperatively.
PATIENTS AND METHODS
Patient Populations
Between October 2004 and May of 2008, 107 patients
with NSCLC deemed potentially operable were enrolled in this
study. All patients included in this study had disease confined to
the chest without evidence of distant metastases and any patient
who received preoperative chemo- or radiotherapy before our
initial blood draw were excluded. The clinicopathologic data for
these patients are outlined in Table 1.
Our standard clinical staging work-up included a com-
puted tomography (CT) scan of the chest (including liver and
adrenal glands) and positron emission tomography (PET)
scan. Magnetic resonance imaging of the brain was included
for bulky disease or symptoms were present. Clinically pos-
itive mediastinal lymph nodes identified by CT (short axis
dimension 1 cm), or hilar–mediastinal nodal PET activity
warranted nodal biopsies via cervical mediastinoscopy or
thoracoscopy.
Patients with pathologically positive mediastinal lymph
nodes (n  36) were treated with either induction or defini-
tive chemotherapy with radiation. Those without evidence of
metastases to the mediastinal lymph nodes were taken to
surgery for a complete anatomic resection of their lung cancer
with lymph node dissection (Table 1). Standard lymph node
dissections of both hilar and mediastinal nodes consisted of
the following: lymph node station levels 2, 4, 7, and 10 for
right upper and middle lobes and levels 2, 4, 7, 8, 9, and 10
for right lower lobes. Left-sided resections sampled lymph
node station levels 5, 6, 7, and 10 for left upper lobes and
levels 5, 6, 7, 8, 9 and 10 for left lower lobes. Surgical
pathology routinely performed hematoxylin and eosin staining
to identify the presence of metastatic disease with immunostain-
ing performed only as indicated to confirm disease origin.
TABLE 1. Patient Demographics
Sex
Male 41
Female 66
Age
Range 14–87
Median 72
NSCLC stage
Clinical Pathological
Ia 38 24
Ib 28 44
IIa 4 2
IIb 13 12
IIIa 8 19
IIIb 2 4
IV 2 0
Not determined 12 2
Histopathological subtype
Adenocarcinoma 62
Adenosquamous 2
Squamous cell carcinoma 31
NSCLC ’other’ 12
Procedure performed
Lobectomy 71
Pneumonectomy 9
Segmectomy 16
Wedge w/biopsy 1
Biopsy/other 10
Clinicopathological characteristics of the tested patient population.
NSCLC, non-small cell lung cancer.
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Patient data, tissue and serum were acquired with written
formal consent and in compliance with the Institutional Review
Board at Rush University Medical Center. Patients were approx-
imately age and sex matched between the groups for nodal
status, with the distribution heavily favoring early-stage disease.
Adenocarcinoma was a 2:1 more common histopathological
subtype than squamous cell carcinoma; with the number of
‘other’ NSCLC subtypes representing only a small portion of the
total patients enrolled in this study. All pathologic staging data
referenced herein were derived from tissue from lymph node
sampling at mediastinoscopy or lymph node dissections accom-
panying tumor resection.
Collection and Storage of Serum Specimens
Peripheral blood was collected from each patient im-
mediately before treatment initiation for NSCLC. Ten milli-
liter of blood was drawn into standard red-top Vacutainers
(without anticoagulants) and coagulated at room temperature
for 30 to 40 minutes. Sera was then separated with centrifu-
gation. Yields ranged 4 to 7 ml of serum per 10 ml of whole
blood. Sera was then immediately divided into aliquots and
archived in an 80°C ultra-low temperature freezer. No
specimens were subjected to more than two thaw cycles for
this study.
Measurement of Serum Biomarker
Concentrations
Luminex xMAP immunobead technology was used
whenever possible for the measurement of circulating
biomarker concentrations reported in this study. This plat-
form offers most of the advantages of conventional sand-
wich immunoassays, but with a much higher throughput
and increased sensitivity over the conventional enzyme-linked
immunosorbent assay (ELISA) assays. The assays were per-
formed according to the respective manufacturer’s instructions
and were conducted in the following groupings; Interleukin-1
(IL-1), IL-1ra, IL-6, IL-8, IL-10, tumor necrosis factor-
(TNF-), and transforming growth factor- Millipore; Bil-
lerica, MA; C-reactive protein (CRP) and serum amyloid A
Millipore; Billerica, MA; epidermal growth factor, basic fibro-
blast growth factor, vascular endothelial growth factor, and
granulocyte colony stimulating factor (G-CSF) Invitrogen;
Carlsbad, CA; death receptor 5 (DR-5), TNF–receptor I (TNF-
RI), and TNF-RII Invitrogen; Carlsbad, CA; Regulated on
Activation, Normal T Expressed and Secreted, macrophage
inflammatory protein-1 (MIP-1), MIP-1, monocyte chemo-
tactic protein-1, and eotaxin Invitrogen; Carlsbad, CA; matrix
metalloproteinases (MMPs) -2, -3, -9, and -13 R&D Systems;
Minneapolis, MN; soluble intracellular adhesion molecule 1
(sICAM 1), sE-selectin, and sP-selectin R&D systems; Minne-
apolis, MN; IL-2, IL-13, interferon- (IFN-), interferon-induc-
ible protein 10, and granulocyte monocyte colony stimulating
factor (GM-CSF) Bio-Rad Laboratories; Hercules, CA; IL-1,
IL-2R, M-CSF, stem cell factor (SCF), and stem cell-derived
factor 1 (SDF-1) Bio-Rad Laboratories; Hercules, CA; and
sEGFR (erb-b1), Her-2 (erb-b2), CA125, CA15–3, CA19–9,
CEA, and CYFRA 21.1 were measured at the University of
Pittsburgh Cancer Institute’s Luminex Core Facility, on a fee-
for-service basis. Biomarker concentrations were calculated
through a five-parametric curve fit as part of the BioPlex Sus-
pension Array System Software v4.0 (Bio-Rad Laboratories;
Hercules, CA). Measurements of TIMP-1 and osteopontin con-
centrations were conducted using commercially-available
ELISA assays and in accordance to the kit directions (R&D
Systems; Minneapolis, MN). Data were collected on a BioTek
PowerWave XS plate reader using KC Junior (v1.40.3) software
package. A four-parametric curve fit was used to calculate the
concentrations from the raw absorbance readings. The ELISA
platform was employed for these two biomarkers due to the lack
of commercially-available Luminex platform assays at the time
of study performance. All assays performed for this study were
conducted in a blinded fashion.
Statistical Methods
Individual biomarker evaluation
Descriptive statistics (median, range) and graphical
displays (histogram, box-plot, normal probability plot) for
the range of concentration values associated with each
biomarker were obtained using SPSS 15.0 for Windows
(SPSS Inc., Chicago, IL). Biomarkers which had more than
one-third of their values outside the range of the assay
were disqualified from further consideration for panel
establishment. For the remaining biomarkers, values which
were reported as missing due to being below the lower
limit of the assay were replaced by the lowest measured
value of that biomarker. A nonparametric Mann-Whitney
rank sum test was then used to assess the difference in
biomarker concentrations according to the preoperative
(pathologic) nodal status (i.e., positive versus negative).
Receiver operating characteristic (ROC) curves for classi-
fying nodal status were calculated for each individual
biomarker using SPSS 15.0. In nearly all cases, our data
compared favorably to previously reported values for the
individual biomarkers.8,19,23–25,28–35 Subgrouping of the
pathologic lymph node positive group into either single or
multiple station involvement was based on intraoperative
nodal dissection with pathologic confirmation. Patients
(n  5) deemed inoperable by our initial evaluation (with
positive mediastinal biopsies) were excluded from these
subgroupings. A nonparametric Mann-Whitney rank sum
test was used to evaluate the association of select biomar-
kers against this surrogate for the extent of nodal involvement.
Multivariate Panel Selection and Analysis
The optimal multivariate panel of biomarkers was
chosen based on variable selection algorithms performed
within the random forests package in R.36,37 We applied
liberal inclusion criteria for the individual biomarkers (a
Mann-Whitney p value smaller than 0.20 or an area under
the ROC curve AUC higher than 0.60) to ensure that no
biomarker with potential value in a multianalyte panel was
prematurely excluded from this selection process based on
a weak individual performance. Briefly, the Random For-
ests package selects optimal combinations of biomarkers
by growing numerous (1000 in the present study) cross-
validated classification trees for each subpanel of biomar-
kers, with each tree used to predict group membership for
each case. These are counted as the tree “votes” for that
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group. The forest chooses the group membership having
the most votes over all the trees in the forest. Each such
tree is grown by cross-validation; where a training set
(approximately two-thirds of the values) is randomly se-
lected from the full data and each tree is grown on this
training data to the largest extent possible (no pruning).
The resultant tree is then used to predict the group mem-
bership for the remaining test cases, which is termed as an
out-of-bag (OOB) prediction. This process is then repeated
1000 times; that is, another training set is randomly se-
lected and a new tree is grown and used to perform another
OOB prediction. The classification accuracy of the random
forest is measured by the averaged error of the OOB
predictions across the entire forest; this is termed the OOB
error rate. The OOB error thus uses disjoint subsets of the
data for model fitting and validation repeatedly. This
cross-validation is also used to compute a variable impor-
tance for each biomarker included in the Random Forest
analysis. The stepwise selection method sequentially
searches for optimal subpanel of markers where the marker
with the lowest variable importance score from the Ran-
dom Forest are removed at each step.
The optimal 6-analyte panel of biomarkers resulting
from the Random Forest variable selection process was
then used by a Classification and Regression Tree (CART)
algorithm to model a classification tree for identifying a
patient’s true (pathologic) preoperative lymph node status.
This analysis was performed using the RPART package of
the R statistical software suite.38 Briefly, classification
trees determine a set of binary if-then logical (split) con-
ditions that permit accurate classification of (in this case)
the patient’s nodal status. The CART algorithm discrimi-
nates between groups by splitting the range of values
measured for each individual biomarker at all of its pos-
sible split points. The ‘goodness of split criterion’ is then
used to determine the best split point for each biomarker
for predicting nodal status. CART then ranks all of the
“best” splits on each biomarker and selects the best bi-
omarker and its split point for the split at the root node.
CART then assigns classes to the two split nodes according
to a rule that minimizes misclassification error. This pro-
cess is continued at each nonterminal child node and at
each of the successive stages until all observations are
perfectly classified or the sample size within a given node
is too small to divide (n  a user-supplied number; such as
5). The final output of the resulting classification tree is a
graphical display of decision criteria for each split, with
the resulting predicted group memberships at the terminal
nodes (Figure 2). The predicted probabilities of preopera-
tive nodal status from the tree were used to obtain sensi-
tivity and specificity across a range of cut-points for
decision rules and the resulting ROC curve. We also
appraised several other classification methods (logistic
regression, neural networks, and support vector machines)
for their ability to correctly predict group classification.
These methods work with linear combinations of biomar-
ker concentrations (instead of splits) and were found to be
less optimal than CART in our application.
RESULTS
Analysis of Individual Serum Biomarkers
According to Pathologic Lymph Node Status
In an effort to establish a multianalyte panel of serum
biomarkers capable of accurately detecting preoperative lymph
node status in NSCLC patients (relative to the pathologic as-
sessments), we selected an array of 47 biomarkers to screen the
sera from 107 NSCLC patients treated at Rush University
Medical Center. The clinical and pathologic characteristics of
the patients are outlined in Table 1. All biomarkers were selected
based either on published reports for each biomarker showing
value for at least one of the following functions: NSCLC
diagnosis, staging, or prognosis8,19,23–25,28–35 or involvement in
biologic processes implicated in disease progression. Several
biomarkers, including IL-1, IL-1, IL-2, IL-15, GM-CSF,
transforming growth factor-, DR5, MMP-13, had a large por-
tion of their overall data set fall below the threshold of assay
range (using the manufacturer’s suggested dilution factor) and
were disqualified from further analysis. No trends in the raw data
from these biomarker candidates were observed to justify re-
evaluation/remeasurement.
Serum concentrations of M-CSF, SCF, IFN-, were
found to be significantly higher in the nodal negative group
(Mann-Whitney two-sided p-values 0.04, 0.01, and 0.01 re-
spectively) whereas the concentration of CRP was found to
be significantly higher in the nodal positive group (p value 
0.03), both relative to pathologic staging. The difference in
MIP-1 concentration between the nodal negative and posi-
tive groups was marginally significant (p value 0.08). In an
effort to avoid the premature exclusion of biomarkers that may
benefit a multianalyte panel, but may not be a satisfactory
predictor individually, we liberally defined the threshold needed
to be considered statistically-relevant to be a ROC analysis
“AUC” value greater than 0.60 or significant Mann-Whitney
rank sum test statistics (i.e., p value) less than 0.20. Based on
these criteria, we found 15 of the original 47 biomarkers to
individually possess value for classifying patient groups based
on lymph node status. MIP-1, SCF, G-CSF, M-CSF,
sICAM-1, TNF-, TNF-RI, TNF-RII, IFN-, sP-selectin, CEA,
IL-2R, osteopontin, CRP and IL-1ra exhibited the most prom-
ising overall profiles. The results of this analysis are presented in
Table 2 and individual analyte profiles displayed as ‘box and
whisker’ plots in Figure 1.
Classifications Based on a Multianalyte Panel
for Identifying Preoperative Nodal Status
A classification tree based on a subpanel of six markers
(consisting of CEA,MIP-1, SCF, TNF-RI, IFN-, and TNF-)
was used with CARTmethodology to predict preoperative nodal
status for our patient population. The classification tree used in
this process is represented in Figure 2. This tree correctly
classified 94 of the 107 cases (a correct classification rate of
88%). The predicted probabilities of being nodal positive from
the tree were used to obtain sensitivity and specificity across a
range of cut-points for decision rules and the resulting ROC
curve is shown in Figure 3. The total area under this ROC curve
(AUC) was at 0.94, with 88% sensitivity and 87% specificity. As
we anticipated, a substantial gain in our ability to predict nodal
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status was achieved by comparing our multianalyte ROC curve
against the ROC curves observed from individual analytes.
The six biomarker panel used for construction of the
classification tree was selected from the 15 biomarker candidates
using variable selection by a Random Forests algorithm. The
averaged OOB misclassification errors from the range of the
1000 trees of the Random Forest grown for each of their
respective subpanels are shown in Table 3. Clearly, we found
that the continued ‘focusing’ of the panel improved our ability to
correctly classify patients relative to the pathologic nodal status.
However, after the 6th iteration these gains approached negligi-
bility, while the range of biologic processes surveyed started to
become limiting. Ultimately, we decided that the optimal bal-
ance of test performance with range of biologic pathways eval-
uated was represented best by the 5th iteration, which provided
a 6-analyte panel (consisting of CEA, MIP-1, SCF, TNF-RI,
IFN-, and TNF-) that is used in the subsequent CART
assessments for preoperative nodal status.
When we evaluated members of our 6-analyte panel
individually against subgroupings of lymph node positive
disease (single- versus multiple-nodal station involvement),
trends in serum biomarker concentrations associated predict-
ably with increasing nodal involvement (Figure 4). This
substudy was performed as a means to confirm the relevance
of the associations of the individual biomarkers with increas-
ing nodal involvement.
There were 13 cases in which lung cancer stage was
classified differently by our blood test relative to pathologic
staging. These consisted of one patient who was erroneously
predicted to have a negative nodal status by our methods, but
was pathologically determined to be node positive, and 12
patients predicted by our blood test to have a positive nodal
status, but were actually (pathologically) node negative. In
comparison, our clinical staging protocols, which are based
on PET and CT-based criteria (described in the Methods
section), provided an 85% accuracy rate for identifying pre-
operative lymph node status, relative to the pathologic stag-
ing. This value is well within the range of published accuracy
figures from other investigators.39,40 Clinical staging (imag-
ing) discrepancies consisted of seven up-staged and eight
down-staged patients upon pathologic staging. With this, we
observed the clinical protocols to be approximately equally
prone to misidentifying a patient’s nodal status relative to the
pathologic assessment, whereas our multianalyte, molecular
approach tended to err towards classifying the patient as
node-positive - requiring that nearly all of the misclassified
patients be down-staged upon pathologic evaluation. Interest-
ingly, only one misclassification was common to both clinical
and molecular staging methods.
DISCUSSION
Surgery remains the mainstay of therapy for localized
NSCLC. In this setting, the status of the locoregional lymph
nodes is the most important prognostic factor.41 When lymph
nodes are involved, the 5-year survival is markedly reduced
compared with stage I node negative patients. In current
National Comprehensive Cancer Network guidelines, when
lymph node metastases are identified, consideration should be
given for adjuvant chemotherapy, as it improves survival.42
As a wide-ranging hypothesis for this study, we rea-
soned that the ‘metastatic phenotype’ responsible for locore-
gional lymph node progression in NSCLC patients is impli-
cated in postoperative disease recurrence. This is likely due to
the presence of undetected occult metastases at the time of
TABLE 2. Individual Biomarkers with Efficacy in Classifying Nodal Status in NSCLC
NSCLC: Node Negativea
(n  71) NSCLC: Node Positivea (n  36)
Biomarker Medianb Rangeb Medianb Rangeb AUC Mann-Whitney U
MIP-1 0.13 0.09–0.70 0.12 0.05–0.81 0.775 0.081
SCF 52.8 13.2–246.4 46.5 16.7–110.4 0.715 0.011
TNF- 14.5 4.5–55.0 13.7 2.9–41.9 0.689 0.141
IL-2R 45.2 2.1–452 47.0 7.0–192.8 0.688 0.598
TNF-RII 1.87 0.32–7.87 1.60 0.22–4.42 0.684 0.223
M-CSF 2.27 0.05–34.7 1.28 0.05–12.0 0.679 0.041
sICAM-1 9608 5148–17,860 10,128 5058–28,376 0.675 0.408
CEA 1392 255–54,741 1,717 255–32,506 0.660 0.191
G-CSF 0.117 0.014–0.070 0.150 0.014–0.580 0.657 0.247
IFN- 33.2 5.7–2258 8.2 5.7–1417 0.629 0.011
TNF-RI 1.69 0.62–8.14 1.41 0.57–8.13 0.623 0.546
Osteopontin 25.3 0–195 22.5 0–190.0 0.616 0.640
IL-1ra 290.7 1.2–5796 321.7 1.1–3258 0.600 0.898
CRP 212.6 1.5–1018.5 293 1.5–992.2 0.576 0.027
MMP-2 6006 3293–12,536 5589 897–10,094 0.568 0.118
aBased on pathologic staging.
bValues expressed as pg/ml.
NSCLC, non-small cell lung cancer; MIP-1, macrophage inflammatory protein; SCF, stem cell factor; TNF, tumor necrosis factor; IFN-, interferon; TNF-RI, tumor necrosis
factor-receptor I; MMP, matrix metalloproteinases; CRP, C-reactive protein; G-CSF, granulocyte colony stimulating factor; sICAM-1, soluble intracellular adhesion molecule 1;
M-CSF, monocyte colony stimulating factor; CEA, carcinoembryonic antigen; IL, Interleukin, AUC, area under the curve.
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surgery. To test this hypothesis, we evaluated a range of
serum analytes associated with NSCLC progression for value
in discriminating preoperative lymph node status in NSCLC
patients, relative to the pathologic assessments. Multivariate
statistical analyses were then used to both identify the optimal
combination of individual analytes relevant for detecting
lymph node metastases and modeling a classification tree for
determining the true (pathologic) nodal status preoperatively.
The 15 biomarkers which correlated most closely with
pathologic nodal status represent a range of biologic pro-
FIGURE 1. Boxplots of biomarker
candidates from the Random Forest
analysis. Box and Whisker plots
were generated for each individual
biomarker in the final iteration of
the Random Forest analysis. Desig-
nations on the abscissa: “0” refers
to lymph node negative, whereas
“1” refers to lymph node positive
(both relative to pathologic stage).
The extreme values are hidden.
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cesses well associated with NSCLC progression. For exam-
ple, a large body of data has been documented that implicates
an inflammatory component to the development and progres-
sion of cancer, regardless of histologic origin.24 Many of
these inflammatory markers are within our top 15 most
relevant biomarkers (e.g., TNF-, TNF-RI, TNF-RII, IFN-
IL-2R, M-CSF, G-CSF, MMP-2, and CRP) and are thought
to be used by tumors to modulate specific effector molecules
involved in metastatic progression. Some (general) examples
of these include IL-8 for neovascularization, MMP and ad-
hesion molecules for tumor cell mobilization and overall
invasive potential.43 In addition, inflammatory molecules can
also induce the production of ‘secondary’ biomarkers in
neighboring cell types, such as the production of sICAM-1 by
tumor-activated T-cells and lung fibroblasts. Biomarkers of
this type typically provide a large degree of signal amplifi-
cation and, therefore, offer excellent sensitivity relative to
primary (tumor-originating) analytes. Although biomarkers
associated with these somewhat generalized pathologic pro-
cesses (such as inflammation) are not expected to lend very
much specificity to the detection of tumor metastasis, they
still may provide prognostic value for clinicopathological
features of the disease. The importance of these “generic”
cancer biomarkers may be punctuated by their inclusion in
other multianalyte biomarker panels; such as those for can-
cers of the head and neck, ovaries, and skin.14,16,17,27 More
specifically, Yurkovetsky et al.16 defined a role of G-CSF,
MIP-1, TNF-, and TNF-RII in distinguishing high-risk
melanoma patients from normal controls, with MIP-1 (and
MIP-1) showing the most promising efficacy in predicting
incidence of disease recurrence. Further examples of the
possible general role the 15 biomarkers found to have a role
in predicting nodal status in NSCLC include: MMP-2, IFN-,
MIP-1, IL-1ra, and G-CSF had diagnostic efficacy in head
and neck cancer,27 CEA had efficacy in predicting liver
metastases in colorectal cancer,44,45 IL-2R had efficacy in
predicting lymph node involvement in breast cancer,46 and
sICAM 1 was revealed from serum proteomics to be able to
predict metastases in nasopharyngeal carcinoma.47
Interestingly, although many of our 15 most relevant
biomarkers have already been well appreciated for their
diagnostic or prognostic significance, not all the molecules in
our ‘top 15 represent biomarkers documented to have any
predictive value for NSCLC, per se. Instead, during the
conceptualization of this study we reasoned that testing mul-
tiple targets of pathways already implicated in various mech-
anistic features of NSCLC progression may lead to the
unveiling of previously unappreciated candidate biomarkers
for diagnostic purposes. For example, members of the active
lymphocytic response (ALR) pathway, such as RANTES and
MIP-1, have already been established to be strongly predic-
tive of patient survival.48 Interestingly, no chemokine in the
ALR pathway previously demonstrated to be prognostic for
NSCLC (including RANTES, MIP-1, MCP-1, eotaxin,
IP-1, IL-8) was found to have significant value in identifying
preoperative lymph node metastases by our examinations.
However, MIP-1, another member of the ALR pathway,
was one of our strongest biomarkers for classifying patients
according to nodal status, despite the fact that it has no docu-
mented record for distinguishing any clinical parameter related
to NSCLC. Along these lines, lymphocytes were also recently
found to be activated by IL-2R after gefitinib administration.49
This interplay between the platelet and lymphocyte activation
mechanisms led us to speculate that IL-2Rmay also have value
for assessing nodal status in NSCLC. Indeed, we found IL-2R
to have considerable value in this capacity and it turned out to be
one of the more discriminating analytes tested in our study. In
another case, the considerable attention focused on the role of
progenitor and stem cells in NSCLC progression50 tempted us to
screen for circulating biomarkers for these cells, including
SDF-1 and SCF. Although Mroczko et al.51 previously estab-
lished a diagnostic role for SCF, to our knowledge we are the
FIGURE 2. Classification and Regression Tree for predicting
preoperative nodal status in non-small cell lung cancer
(NSCLC) patients. A binary ‘if-then’ set of decision rules is
used to split the data into separate branches of the tree with
each node of the tree displaying the appropriate analyte and
threshold concentrations. Additional classifications continue
to the left if the threshold is not met, and to the right if the
value is equal to or exceeding this cutoff. The number of
classifications (observations) are listed immediately below
each terminal node, with each final arm labeled (0  node
negative; 1  node positive).
FIGURE 3. Receiver operator characteristic curve for the
most robust staging subpanel generated by the Random
Forest analysis. Area under the curve  0.94; Sensitivity 
88%; Specificity  87%.
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first to report associations for this biomarker with locoregional
metastatic progression in NSCLC. Given the resistance of stem
cells to traditional lines of chemotherapy52 and the apparent
relationship circulating SCF has for detecting lymph node me-
tastases, it would be of great interest to further investigate the
role of stem cells in the establishment of secondary metastases in
NSCLC as well as the risk for disease recurrence.
Our 6-analyte panel was able to accurately identify
lymph node involvement in 88% of the NSCLC patients
tested, relative to the gold-standard of pathologic staging.
Recently, the integration of CT and PET has emerged as
the most effective protocol for clinically staging patients
preoperatively. Although the accuracy of integrated
PET/CT scans to classify patients according to nodal status
ranges considerably in the literature, recent comparisons
(preoperative clinical staging versus intraoperative his-
topathological staging) provided figures in the range of 78
to 90%. They have a dramatic loss in accuracy and spec-
ificity with nodes 1 cm or relevant comorbidities.39,40 We
were able to correctly identify lymph node metastases in
85% of the patients enrolled in this study, which agrees
favorably with the documented accuracy rates mentioned
above. Although the errors for clinically evaluating our
patients were equally divided between up- and down-
staging, we observed a strong trend for our ‘molecular
staging’ method to ‘up-stage’ the patients (i.e., predict a
positive nodal status in a pathologically-determined node
negative case). No obvious trend towards disease recur-
rence was observed in these misclassified patients within
the framework of the available clinical follow-up data.
Such an observation would clearly have been highly sug-
gestive of the presence of occult metastases at the time of
surgery. Interestingly, only a single misclassification out
of the total patient population enrolled in this study was
observed by both imaging and blood-based methods. This
observation is highly suggestive that the molecular and
clinical staging methods may be complementary, and the
combination of a blood-based assay with PET/CT imaging
may show the most promise for identification of patients
who are candidates for systemic therapy.
Several major concerns are typically raised during
the development of multianalyte diagnostic tests that man-
TABLE 3. Variable Selection Using Random Forests of the 15 Biomarker Candidates
Biomarkers
Variables MIP-1 SCF CEA TNF-RI TNF- IFN- M-CSF G-CSF TNF-RII sICAM-1 MMP-2 CRP IL-2R OP IL-1ra OOB
1 15 X X X X X X X X X X X X X X X 0.336
2 12 X X X X X X X X X X X X 0.308
3 10 X X X X X X X X X X 0.308
4 8 X X X X X X X X 0.317
5 6 X X X X X X 0.308
6 5 X X X X X 0.289
7 4 X X X X 0.345
MIP-1, macrophage inflammatory protein; SCF, stem cell factor; TNF, tumor necrosis factor; IFN-, interferon; TNF-RI, tumor necrosis factor-receptor I; MMP, matrix
metalloproteinases; CRP, C-reactive protein; G-CSF, granulocyte colony stimulating factor; OP, osteopontin; sICAM-1, soluble intracellular adhesion molecule 1; M-CSF, monocyte
colony stimulating factor; CEA, carcinoembryonic antigen; IL, interleukin; OOB, out-of-bag.
FIGURE 4. Boxplots of the 6-ana-
lyte biomarker panel for identifying
preoperative nodal status with re-
spect to extent of nodal station in-
volvement. Boxplots for the 6-ana-
lytes comprising our most optimal
panel for predicting lymph node
involvement are represented with
the node positive subjects subdi-
vided according to either single or
multiple nodal station involvement
as a surrogate for total nodal in-
volvement. (Mann-Whitney p-val-
ues: *, p  0.011; **, p  0.07;
**, p  0.012).
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date a series of additional validation steps to suitably
appraise the value of the test before clinical application.
Recently, Brenner et al.53 defined these factors as the
following: (1) over-fitting the data with multiparametric
statistical models, (2) bias from inappropriate patient se-
lection, and (3) bias inherent to the specific patient popu-
lation being studied that is not generally true across the
total population. We were careful to obviate concerns 1
and 2 by cross-validating our results across several mul-
tiparametric statistical models (as defined in the Results
section) and relying on the clinical expertise of our re-
search team to select an appropriate and representative
patient population for this study. To address concern 3,
Pepe et al.54 proposed a five-phase validation sequence that
specifically defines the aims, specimen selection, and pri-
mary outcome measures necessary in each phase of bi-
omarker development. This validation scheme has been
adopted by the Early Detection Research Network and,
indeed, is required for this diagnostic tool to progress
towards clinical application. Specifically, we are planning
additional validation against a much larger serum cohort
that has been accrued by the NCI-sponsored ‘Cancer and
Leukemia Group B.’
Once our multianalyte serum biomarker panel has
been properly validated against a second, independent
serum cohort, we expect that one of the principal outcomes
will be an improved modality for the preoperative selec-
tion of patients requiring systemic treatment. This may be
particularly valuable given that neoadjuvant chemotherapy
is generally better tolerated than adjuvant (postoperative)
chemotherapy. Therefore, with more accurate staging
methods, patients would receive more appropriately admin-
istered chemotherapy, thereby decreasing the overall morbidity
of NSCLC treatments. In the future, we anticipate developing a
series of multianalyte blood tests that will be capable of identi-
fying specific mechanistic details of disease progression and
allow for the individualization of patient therapies with existing
targeted or multimodal therapies. In addition to providing more
effective and better tolerated treatment options for patients, this
paradigm is also expected to lead to the development of new
targeted therapies through an improved understanding of the
biology of the disease. We predict this insight will allow us to
more effectively treat patients with NSCLC and, thereby im-
prove survival.
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